Drug Approval | March 07, 2025
Briefs: Alembic Pharma and IOL Chemicals and Pharmaceuticals
USFDA inspection at Alembic Pharma's Bioequivalence facility
USFDA inspection at Alembic Pharma's Bioequivalence facility
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
ANVIMO will be available in dosages of 240 mg and 480 mg
The company will provide the necessary response on these observations to USFDA within stipulated 15 days
Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
Subscribe To Our Newsletter & Stay Updated
